Skip to content

Search

Showing results for "1"

ATAR special provisions still open for newly diagnosed

The deadline for ATAR exam special provisions is still open for newly diagnosed Type 1 Diabetes patients.

Diabete$ Re$earch in Au$tralia

It may surprise you to know that the Australian government has invested almost $300 million dollars since 2000 towards research and clinical trials for diabetes

Rio Tinto Children’s Diabetes Centre Scholarships

Honours/Masters scholarship - now open Applications are open for our Honours / Masters Scholarships with the purpose of providing funding for

Advances in Automated Insulin Delivery with the Medtronic 780G: The Australian Experience

To assess the real-world performance of MiniMed™ 780G for Australians with type 1 diabetes (T1D) following advanced hybrid closed loop (AHCL) activation and to evaluate the effect of changing from MiniMed 670/770G to 780G.

Six months of hybrid closed-loop therapy improves diabetes-specific positive well-being, and reduces diabetes distress and fear of hypoglycemia: secondary analysis of a controlled trial

This analysis aimed to investigate diabetes-specific psychological outcomes among adults with type 1 diabetes (T1D) using hybrid closed-loop (HCL) versus standard therapy. 

Copeptin Kinetics and Its Relationship to Osmolality During Rehydration for Diabetic Ketoacidosis in Children

Copeptin is a surrogate marker for arginine vasopressin (AVP) release in response to hyperosmolal stimuli such as diabetic ketoacidosis (DKA). The objective of this work is to characterize kinetics of copeptin and osmolality, and their dynamic relationship during rehydration and insulin therapy in children with type 1 diabetes (T1D) and DKA.

Cohort profile: Pregnancy and childhood epigenetics (PACE) consortium

Currently, DNA methylation is the most studied epigenetic phenomenon in large populations

A Cost-Effectiveness Analysis of Sensor-Augmented Insulin Pump Therapy and Automated Insulin Suspension versus Standard Pump Therapy

A clinical trial-based economic evaluation was performed in which the net costs and effectiveness of the two treatment modalities were calculated and...

Duration of protection after first dose of acellular pertussis vaccine in infants

Without a booster dose, the effectiveness of 3 doses waned more rapidly from 2 to 4 years of age than previously documented for children >6 years of age who...